What Is PT-141 (Bremelanotide)? Sexual-Function Research

PT-141, known scientifically as bremelanotide, is a cyclic heptapeptide that has become one of the most discussed compounds in sexual-health research. Unlike most drugs studied for sexual function, which act locally on blood vessels, PT-141 is notable for acting centrally, in the brain’s melanocortin signaling system. This article summarizes what the research literature says about its mechanism, its clinical history — including the FDA-approved product Vyleesi — and how it differs from unregulated “research-grade” material. Everything below is provided strictly for research and educational purposes only.

What is PT-141 (Bremelanotide)?

PT-141 is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (α-MSH), developed as a more selective analog of an earlier compound, Melanotan II. Researchers modified Melanotan II’s structure to reduce activity at MC1R (the receptor responsible for skin pigmentation) while preserving activity at MC3R and MC4R, the receptor subtypes most implicated in sexual behavior regulation (Diamond et al., 2004).

It is important to distinguish two related but separate things:

• Bremelanotide / Vyleesi — the FDA-approved subcutaneous injection (marketed by Palatin Technologies) indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a fixed 1.75 mg dose on an as-needed basis under medical supervision.
• PT-141 research material — unregulated peptide sold for laboratory and research use, not manufactured, tested, or labeled to pharmaceutical standards, and not intended for human administration.

These are not interchangeable. Vyleesi is a regulated medicine with defined manufacturing, dosing, and prescribing information; research-grade PT-141 has none of that oversight. This article discusses the underlying peptide and its published research literature, not a recommendation to use unregulated material.

Mechanism of Action

Central, not peripheral, activity

Most drugs developed for sexual dysfunction — phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil or tadalafil — work peripherally, relaxing vascular smooth muscle to increase blood flow. PT-141 works differently: it is a melanocortin receptor agonist that acts primarily within the central nervous system, particularly in hypothalamic and limbic circuits.

MC4R and MC3R signaling

When bremelanotide binds MC4R (and, to a lesser extent, MC3R), it activates Gs-protein-coupled signaling, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). Melanocortin receptors of this type are densely expressed in brain regions long associated with sexual behavior, including the hypothalamus, amygdala, and nucleus accumbens.

Downstream dopaminergic pathways

Preclinical work has linked melanocortin receptor activation in the medial preoptic area (MPOA) of the hypothalamus to increased dopaminergic neurotransmission, a pathway implicated in motivational and appetitive aspects of sexual behavior in animal models (Pfaus, Giuliano & Gelez, 2007). This central, motivation-related mechanism is the main reason bremelanotide is described as acting on sexual desire, in contrast to drugs that act purely on the physical mechanics of arousal.

Research Background & Key Findings

The clinical research trail behind bremelanotide is unusually well documented for a peptide of this kind, spanning intranasal formulations tested in men, and later subcutaneous formulations tested in women.

1. 1

   2004

   Diamond et al. — double-blind intranasal PT-141 study in healthy men and men with mild-to-moderate ED.

2. 2

   2007

   Pfaus et al. — preclinical review of central melanocortin effects on female sexual function.

3. 3

   2019

   Phase 3 RECONNECT trials — over 1,200 premenopausal women with HSDD, subcutaneous 1.75 mg.

4. 4

   June 2019

   FDA approves bremelanotide (Vyleesi) — first melanocortin agonist for sexual dysfunction.

• Early intranasal studies in men. Diamond and colleagues conducted a double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and men with mild-to-moderate erectile dysfunction, reporting dose-related effects on erectile function alongside a manageable safety and pharmacokinetic profile (Diamond et al., International Journal of Impotence Research, 2004).
• Preclinical CNS mechanism work. Pfaus, Giuliano, and Gelez reviewed preclinical evidence for bremelanotide’s central nervous system effects on female sexual function, describing melanocortin pathways linking hypothalamic receptor activation to sexual motivation in animal models (Journal of Sexual Medicine, 2007).
• Phase 3 RECONNECT trials in women. Kingsberg and colleagues reported results of two randomized, placebo-controlled phase 3 trials (the RECONNECT studies, enrolling over 1,200 premenopausal women with HSDD) showing statistically significant improvements in sexual desire and desire-related distress with on-demand subcutaneous bremelanotide 1.75 mg (Kingsberg et al., Obstetrics & Gynecology, 2019).
• Long-term safety follow-up. A companion open-label extension study by Simon and colleagues examined longer-term safety and efficacy, reporting that nausea, flushing, and headache were the most common treatment-related adverse events, generally mild-to-moderate and diminishing with continued exposure (Simon et al., Obstetrics & Gynecology, 2019).
• Regulatory outcome. These phase 3 trials supported FDA approval of bremelanotide (Vyleesi) in June 2019 for HSDD in premenopausal women, making it the first melanocortin receptor agonist approved for a form of sexual dysfunction.

Despite this relatively mature female-indication dataset, a large, published phase 3 program specifically for male sexual dysfunction has not been completed, and bremelanotide is not FDA-approved for men. Men-focused findings remain limited to earlier phase 2-level and mechanistic work, so claims about efficacy in male populations should be treated as preliminary rather than established.

Forms, Reconstitution & Handling

Research-grade PT-141 is typically supplied as a lyophilized (freeze-dried) powder in a sealed vial, which must be reconstituted with bacteriostatic water before use in a laboratory setting. General handling principles that apply across most reconstituted peptides — sterile technique, avoiding excessive agitation, and accurate volume measurement — are outlined in the peptide reconstitution guide. Where information relates to administration technique in general research contexts, the injection best practices overview covers common considerations such as needle handling and site rotation. Product-specific research material is listed on the PT-141 10mg page, including any available documentation on identity and purity.

Research Considerations (General, Non-Instructional)

Because bremelanotide’s approved clinical use (Vyleesi) involves a fixed, medically supervised dose in a specific population, findings from that population do not automatically generalize to other contexts. Researchers examining PT-141 in a laboratory setting typically consider factors such as:

• The timing of administration relative to the behavioral or physiological endpoint being measured, since central melanocortin effects in published pharmacokinetic work appear over a period of hours rather than minutes.
• The distinction between central (desire/motivation) and peripheral (vascular) endpoints, since these reflect different mechanisms and should not be conflated when interpreting outcomes.
• Individual variability in melanocortin receptor sensitivity and in commonly reported effects such as transient nausea or flushing, which appear frequently across the published clinical literature.

None of the above constitutes dosing instructions or medical guidance; it describes general variables that appear in the published research literature.

Storage & Stability

As with most peptides, storage conditions affect research material integrity:

• Lyophilized powder: typically stored at approximately -20°C (a standard freezer), generally considered stable for an extended period when protected from light and moisture.
• Reconstituted solution: typically stored refrigerated at 2–8°C and used within a limited window, commonly cited as several weeks, though exact stability depends on formulation and handling.
• General handling: avoid repeated freeze-thaw cycling and prolonged exposure to light or room temperature, both of which can accelerate peptide degradation.

Safety, Legality & Research Disclaimers

Bremelanotide as the approved product Vyleesi carries FDA-reviewed prescribing information, including known adverse effects such as nausea, flushing, injection-site reactions, headache, and transient increases in blood pressure, which is why it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease and requires medical supervision.

Research-grade PT-141 is not Vyleesi. It is sold without pharmaceutical manufacturing standards, without a Certificate of Analysis guarantee, and without any regulatory review for human use. It should be handled strictly as a laboratory research chemical:

• Not for human or animal self-administration
• Not evaluated for the manufacturing consistency, sterility, or purity guarantees that regulated pharmaceuticals require
• Subject to jurisdiction-specific legal restrictions that researchers must independently verify
• Not a substitute for medical consultation regarding sexual health concerns, which should be directed to a licensed healthcare provider

Nothing in this article constitutes medical advice, and no dosing information here should be interpreted as instructions for human use.

Frequently Asked Questions

Is PT-141 the same as Vyleesi? They share the same active molecule, bremelanotide, but Vyleesi is a regulated, FDA-approved pharmaceutical product with defined manufacturing and prescribing standards. Research-grade PT-141 sold for laboratory use has none of these guarantees and is not equivalent to the approved drug.

How does PT-141 differ from PDE5 inhibitors like sildenafil? PDE5 inhibitors act peripherally, relaxing vascular smooth muscle to support blood flow. PT-141 is a melanocortin receptor agonist thought to act centrally, in hypothalamic and limbic brain circuits associated with sexual motivation and desire, a mechanistically distinct pathway.

Is PT-141 approved for use in men? No. Vyleesi is approved only for hypoactive sexual desire disorder in premenopausal women. Male-focused data comes largely from earlier-phase and mechanistic studies; a completed phase 3 program for men has not been published, so claims of proven efficacy in men remain preliminary.

What side effects are reported in the clinical literature? Phase 3 and long-term extension studies of bremelanotide report nausea, flushing, and headache as the most common treatment-related effects, generally mild-to-moderate, along with transient blood pressure increases that warrant caution in people with cardiovascular risk factors.

Is research-grade PT-141 legal to purchase? Legal status varies by jurisdiction and is subject to change. Researchers are responsible for independently verifying local regulations. This article does not constitute legal advice.

Can PT-141’s mechanism be studied outside of sexual function? Because MC3R/MC4R signaling is involved in broader hypothalamic regulation, including appetite and energy balance, some preclinical research has examined melanocortin agonists in other contexts, but this is separate from, and should not be conflated with, its studied role in sexual desire.

References

1. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. “Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.” International Journal of Impotence Research. 2004;16(1):51-59.
2. Pfaus JG, Giuliano F, Gelez H. “Bremelanotide: an overview of preclinical CNS effects on female sexual function.” Journal of Sexual Medicine. 2007;4(Suppl 4):269-279.
3. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics & Gynecology. 2019;134(5):899-908.
4. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. “Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.” Obstetrics & Gynecology. 2019;134(5):909-917.
5. U.S. Food and Drug Administration. Approval of Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women, June 2019.

---

Last updated: July 4, 2026

Disclaimer: This information is for educational and research purposes only. Research-grade PT-141 is a laboratory research chemical, not an approved medicine, and is not intended for human consumption or self-administration. This is not medical advice.